(2024) developed non-cleavable CD47-targeting ADCs (7DC2-DM1, 7DC4-DM1) showing near-complete tumor inhibition in CRC and lung cancer models with improved safety versus cleavable constructs (73). Here, CD47 is linked to neoplasm.